-
公开(公告)号：US20190202873A1
公开(公告)日：2019-07-04
申请号：US16359267
申请日：2019-03-20
申请人： Wyeth LLC
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20130330371A1
公开(公告)日：2013-12-12
申请号：US13970048
申请日：2013-08-19
申请人： WYETH LLC
发明人： Annaliesa Sybil Anderson , Maninder K. Sidhu , Robert G. K. Donald , Kathrin Ute Jansen , Narender Kumar Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：USRE46376E1
公开(公告)日：2017-04-25
申请号：US14883000
申请日：2015-10-14
申请人： WYETH LLC
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20150125927A1
公开(公告)日：2015-05-07
申请号：US14529147
申请日：2014-10-31
申请人： WYETH LLC
发明人： Mark E. Ruppen , Justin Keith Moran , Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G. K. Donald , Narender K. Kalyan , Maninder K. Sidhu , Michael James Flint
IPC分类号： C12N9/10
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US08557548B2
公开(公告)日：2013-10-15
申请号：US13848909
申请日：2013-03-22
申请人： Wyeth LLC
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US20200095290A1
公开(公告)日：2020-03-26
申请号：US16704777
申请日：2019-12-05
申请人： Wyeth LLC
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：US09745354B2
公开(公告)日：2017-08-29
申请号：US14529147
申请日：2014-10-31
申请人： WYETH LLC
发明人： Mark E. Ruppen , Justin Keith Moran , Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G. K. Donald , Narender K. Kalyan , Maninder K. Sidhu , Michael James Flint
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：USRE46518E1
公开(公告)日：2017-08-22
申请号：US15366702
申请日：2016-12-01
申请人： Wyeth LLC
发明人： Annaliesa Sybil Anderson , Maninder K. Sidhu , Robert G. K. Donald , Kathrin Ute Jansen , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
CPC分类号： C07K14/33 , A61K39/08 , C07K16/1282 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C12N9/1051 , C12N9/99 , C12N15/74
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：USRE48863E1
公开(公告)日：2021-12-28
申请号：US16388011
申请日：2019-04-18
申请人： WYETH LLC
发明人： Annaliesa Sybil Anderson , Maninder K. Sidhu , Robert G. K. Donald , Kathrin Ute Jansen , Narender K. Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号：USRE48862E1
公开(公告)日：2021-12-28
申请号：US16387999
申请日：2019-04-18
申请人： WYETH LLC
发明人： Maninder K. Sidhu , Annaliesa Sybil Anderson , Robert G. K. Donald , Kathrin Ute Jansen , Narender K. Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.035 秒)
